FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read FDA & Regulatory Intelligence Witfire Elite View FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma Then the Door Reopened: A Regulatory Whiplash Case Study RP1 showed a roughly one-in-three response rate, durable activity, and…
Trending News
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
The stock market is now looking at the US-Israel-Iran conflict through a sharper…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
The US-Israel-Iran war is affecting pharma stocks, drug supply chains, logistics costs, cold-chain…
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy…
Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
Iran War Pharma Shock: India API Dependence vs China Biotech Chokepoints | Witfire…
Editorial picks
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma
India CRO Boom: Why India’s Next CRO Boom May Be Built on Molecules It Did Not Invent
Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
CagriSema May Not Be Enough to Restore Novo Nordisk’s Obesity Lead
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read FDA & Regulatory Intelligence Witfire Elite View FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma Then the Door Reopened: A Regulatory Whiplash Case Study…
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk
Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion
IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections
Categories
Investments
business news
Entrepreneurship
Startups
2026
INSIGHTS FOR THE NEW PHARMA LEADERS
Witfire Elite brings focused perspectives on pharma growth, innovation, manufacturing, startups, and executive strategy.
Around The World
Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
Iran War Pharma Shock: India API Dependence vs China Biotech Chokepoints | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View Iran War Pharma Shock Why India’s API Dependence Hurts More Than China’s Biotech Lead The Iran war and Strait of Hormuz disruption expose a deeper pharma asymmetry: India dominates…
Pharma News
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma | Witfire Elite View Witfire Elite FDA &…
India CRO Boom: Why India’s Next CRO Boom May Be Built on Molecules It Did Not Invent
India CRO Boom: Why Chinese Molecules May Build the Next Outsourcing Wave | Witfire Elite View Witfire Elite…
Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
Iran War Pharma Shock: India API Dependence vs China Biotech Chokepoints | Witfire Elite View Witfire Elite Pharma…